概览

转眼瞬间已九载，凝神常思向十年。2018年，DIA中国年会将迎来10周岁。

十年前，当中国尚未全面参与国际多中心临床试验时，DIA来到中国，在北京主办召开了以“从‘平坦世界’的视角看药物研发：创新、法规和全球化”为主题的第一届中国年会。自2009年首届年会以来，DIA在中国的十年，是见证中国医药风雨兼程地从传统制药走向自主创新的十年，是中国医药健康产业蓬勃发展的十年，也是见证中国药监改革快速发展硕果累累的十年。刚刚过去的两年中，国家食品药品监督管理局（CFDA）已经展示了前所未有的决心，推出了一系列措施深化制度改革，确保公众用药的有效性与安全性。

2017年5月21日，在上海国际会议中心举办的第九届DIA中国年会上，CFDA--DIA联合举办的有关ICH的研讨会向世界传递了来自中国的坚定的声音。2017年6月，CFDA正式加入ICH标志了中国药监历史上的一个重要的里程碑。

2018年，第十届DIA中国年会，DIA亚洲最大的跨学科盛会，您是否想参加？您是否想在中国生命科学创新如此激动人心的时刻为非凡事件贡献一份力量？

第十届 DIA 中国年会设有壁报展览。这是一个交流知识和经验，应用新技术和新方法的良机。

精选主题

开幕特别论坛
监管科学
CFDA专场
创新性突破治疗（肿瘤、心血管疾病等）
临床开发（运营、基地、GCP等）
定量科学
CMC及仿制药
生物制品及生物类似物开发
医学事务
药物安全与药物警戒
患者参与
医疗健康的大数据研究与人工智能
医疗器械、伴随诊断、IVD
热点话题（罕见病、心血管领域多方合作、投资与商务拓展、Portfolio管理、支付方等）

项目委员会

Pei HU Director, Phase I Unit, Clinical Pharmacological Research Center
Peking Union Medical College, China
Bin Xue Director-General
China Center for Food and Drug International Exchange, NMPA, China
Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Senior Advisor
BeiGene (Beijing) Co., Ltd., China
Irene Deng Head of Regulatory Affairs, China
Sanofi, China
Jin Cui Program Officer
China Center for Food and Drug International Exchange , China
George LIU Head of Early Development and Scientific Operation
Harbour Biomed, China
Zhiqiang Ning Vice President, Research & Clinical Development
Shenzhen Chipscreen Biosciences, Ltd., China
Jessica Liu, MD VP, Head of Merges and Acquisition Management Department
Tigermed Consulting Co., Ltd, China
Sunny Zhu Chief Medical Officer, Infectious Diseases
Everest Medicines, China
Hannah Chen, MD Consultant
Beijing XiaoTongMingDa Technology Ltd., China
Paul Dai, MD Head of Clinical Operations
TDC, Asia, Takeda, China
Reako Ren Head of SMO Services
WuXi AppTec, China
Connie Dai
Graceful Plume, China
Hualong Sun General manager
Meta Clinical Technical Co. Ltd, China
Charles Yan Vice President, Head of Clinical Data Science Center
Jiangsu Hengrui, China
Melly Lin, MS Regional Policy Lead
F. Hoffmann-La Roche Ltd, Switzerland
Joe Zhang Co-founder and CEO
BJ Bioscience Inc., China
Xiangyang Zhu CEO
Shanghai Huaota Biopharma Co., Ltd, China
Li L Wang Global Senior Vice President & Head, Lilly China Drug Development & Medical Affa
Eli Lily & Company, China
Xiaoling Wang Clinical Documentation
Clinical Science Operation, Sanofi R&D China, China
Xue TANG Drug Safety Unit Regional Head (DRH),
APAC Pfizer, China
Dayao ZHAO, MD, PhD Former Vice President and Lead, China Drug Development
Pfizer, China
Jane Y. Cai, PhD Former Managing Director
DIA China, China
Tony Guo Executive Director, Head of Biometrics China
BeiGene, China
Tong Guo CEO
GEM Flower Pharma Tech, China
Amber Wang Vice President, Regulatory Affairs & QA
SmithNephew, China
Ruyi He, MD Chief Scientist
Center for Drug Evaluation, CFDA, United States
Jingsong Wang, MD Founder, Chairman, and Chief Executive Officer
Harbour BioMed, China
Shun Lu Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital,
Shanghai Jiaotong University, China
Xianglin Zhang President
Shenyang Pharmaceutical University, China
Carol Zhu, MBA Vice President, Portfolio and Project Management
JW Therapeutics, China
Ron Fitzmartin, PhD, MBA Senior Advisor, Office of Regulatory Operations, CBER
FDA, United States
Murray M. Lumpkin, DrMed, MD, MSc Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative
Bill and Melinda Gates Foundation, United States
Kenneth Getz, MBA Tufts Center for the Study of Drug Development
Tufts University School of Medicine, United States
Sandy Milligan, JD, MD Board of Director Member, Gossamer Bio; Principal
Innovex Strategies, United States
Ling Su, PhD Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China